Enhanced anti-tumor activity of CD5 CAR T cells manufactured with tyrosine kinase inhibitors in patients with relapsed/refractory T-ALL. This is an ASCO Meeting Abstract from the 2023 ASCO Annual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results